Designer drugs – A continuing chemical (R)evolution

[1]  D. Crich,et al.  Assessing the role of dopamine in the differential neurotoxicity patterns of methamphetamine, mephedrone, methcathinone and 4-methylmethamphetamine , 2017, Neuropharmacology.

[2]  P. Armenian,et al.  Intoxication from the novel synthetic cannabinoids AB-PINACA and ADB-PINACA: A case series and review of the literature , 2017, Neuropharmacology.

[3]  T. Dickerson,et al.  Locomotor and reinforcing effects of pentedrone, pentylone and methylone in rats , 2017, Neuropharmacology.

[4]  H. Sitte,et al.  Fluorinated phenmetrazine “legal highs” act as substrates for high-affinity monoamine transporters of the SLC6 family , 2017, Neuropharmacology.

[5]  Brenda M Gannon,et al.  Phencyclidine-like in vivo effects of methoxetamine in mice and rats , 2017, Neuropharmacology.

[6]  K. Rice,et al.  Role of monoaminergic systems and ambient temperature in bath salts constituent 3,4-methylenedioxypyrovalerone (MDPV)-elicited hyperthermia and locomotor stimulation in mice , 2017, Neuropharmacology.

[7]  Jill Barr-Walker,et al.  Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review , 2017, Neuropharmacology.

[8]  K. Rice,et al.  Relative reinforcing effects of second-generation synthetic cathinones: Acquisition of self-administration and fixed ratio dose-response curves in rats , 2017, Neuropharmacology.

[9]  G. Pasternak,et al.  Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace , 2017, Neuropharmacology.

[10]  M. Liechti,et al.  Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs) , 2017, Neuropharmacology.

[11]  S. Perrine,et al.  Repeated exposure to 3,4-methylenedioxypyrovalerone and cocaine produces locomotor sensitization with minimal effects on brain monoamines , 2017, Neuropharmacology.

[12]  B. Thomas,et al.  Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists , 2017, Neuropharmacology.

[13]  A. Benyamina,et al.  MDPV and α-PVP use in humans: The twisted sisters , 2017, Neuropharmacology.

[14]  O. Grundmann,et al.  The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse , 2017, Neuropharmacology.

[15]  Z. Cooper,et al.  Methodology for controlled administration of smoked synthetic cannabinoids JWH-018 and JWH-073 , 2017, Neuropharmacology.

[16]  M. Olive,et al.  Neurocognitive dysfunction following repeated binge-like self-administration of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV) , 2018, Neuropharmacology.

[17]  S. Krähenbühl,et al.  Pharmacological profile of mephedrone analogs and related new psychoactive substances , 2017, Neuropharmacology.

[18]  S. Krähenbühl,et al.  Pharmacological profile of methylphenidate-based designer drugs , 2017, Neuropharmacology.